Dice Therapeutics Inc (DICE)

$25.16 -22.39 (-47.08%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 600
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts Sell
Price Target $53.73
ETFdb
ETFdb Sep. 11 at 4:15 PM
Prediction markets have a new ETF. So do the tiny components helping power AI hardware. These are two funds among this week’s launches, and they show just how specific ETF strategies are getting. 1️⃣ $HQDG takes a quality approach to dividend growth 2️⃣ $DICE targets trading and prediction markets 3️⃣ $CCML focuses on electronic components tied to AI hardware 4️⃣ $VEEM looks to analyst sentiment across emerging markets Which one are you watching? 👉 Let us know, and sign up for the ETFDb newsletter for daily ETF news and insights: https://etfdb.com/newsletter/?source=stocktwits #ETFs #ETF #Investing #Markets
0 · Reply
NVDAMillionaire
NVDAMillionaire Jan. 14 at 11:34 PM
$DICE DICE Therapeutics, Inc. (NASDAQ:DICE): A Promising Biopharmaceutical Company Poised for Growth https://beyondspx.com/article/dice-therapeutics-inc-nasdaq-dice-a-promising-biopharmaceutical-company-poised-for-growth
0 · Reply
Quantumup
Quantumup Nov. 22 at 1:10 PM
BTIG⬆️PT $PTGX $67 was $51/Buy, after ascribing💳to PN-881 based on the implied EV of $DICE's ACQ by $LLY, (on only P1 data), risk adj'd by 50%. BTIG thinks PN-881's differentiated specificity could support preferential positioning as the dominant oral IL-17 inhibitor: $UCBJY $NVS
0 · Reply
NVDAMillionaire
NVDAMillionaire Aug. 22 at 5:48 AM
$DICE DICE Therapeutics, Inc. (NASDAQ:DICE): A Promising Biopharmaceutical Company Poised for Growth http://beyondspx.com/2024/08/04/dice-therapeutics-inc-nasdaqdice-a-promising-biopharmaceutical-company-poised-for-growth/
0 · Reply
valueforme
valueforme Aug. 21 at 5:10 AM
$PRQR By "like these" he meant $DICE and $MORF deals, early ish stage assets, novel science.
0 · Reply
macroaxis
macroaxis Aug. 14 at 11:17 PM
$NERV - Investment perspective on Minerva Neurosciences vs. Dice Molecules ( $DICE ) in September 2023. Next fiscal quarter end is on 30th of September 2023 https://www.macroaxis.com/competition/NERV/DICE/Minerva-vs-Dice #portfolio_prospective #better_portfolio #diversify
0 · Reply
ChartMill
ChartMill Aug. 11 at 4:24 PM
$NVO, $DICE and $BLDR. Strong technicals stocks and near a new high. https://www.chartmill.com/stock/stock-screener?sid=16&f=p_pg10,v1_50b500,s_str,s_nnh,exch_us&v=3&timeframe=DAILY&type=CANDLES&months=0.05&width=720&cl=F&o1=3&o2=3&o3=1&op1=200,16711680&op2=50,255&utm_source=Strong_Stocks_near_New_High&utm_medium=stocktwits&utm_campaign=screen
0 · Reply
Latest News on DICE
No data available.
ETFdb
ETFdb Sep. 11 at 4:15 PM
Prediction markets have a new ETF. So do the tiny components helping power AI hardware. These are two funds among this week’s launches, and they show just how specific ETF strategies are getting. 1️⃣ $HQDG takes a quality approach to dividend growth 2️⃣ $DICE targets trading and prediction markets 3️⃣ $CCML focuses on electronic components tied to AI hardware 4️⃣ $VEEM looks to analyst sentiment across emerging markets Which one are you watching? 👉 Let us know, and sign up for the ETFDb newsletter for daily ETF news and insights: https://etfdb.com/newsletter/?source=stocktwits #ETFs #ETF #Investing #Markets
0 · Reply
NVDAMillionaire
NVDAMillionaire Jan. 14 at 11:34 PM
$DICE DICE Therapeutics, Inc. (NASDAQ:DICE): A Promising Biopharmaceutical Company Poised for Growth https://beyondspx.com/article/dice-therapeutics-inc-nasdaq-dice-a-promising-biopharmaceutical-company-poised-for-growth
0 · Reply
Quantumup
Quantumup Nov. 22 at 1:10 PM
BTIG⬆️PT $PTGX $67 was $51/Buy, after ascribing💳to PN-881 based on the implied EV of $DICE's ACQ by $LLY, (on only P1 data), risk adj'd by 50%. BTIG thinks PN-881's differentiated specificity could support preferential positioning as the dominant oral IL-17 inhibitor: $UCBJY $NVS
0 · Reply
NVDAMillionaire
NVDAMillionaire Aug. 22 at 5:48 AM
$DICE DICE Therapeutics, Inc. (NASDAQ:DICE): A Promising Biopharmaceutical Company Poised for Growth http://beyondspx.com/2024/08/04/dice-therapeutics-inc-nasdaqdice-a-promising-biopharmaceutical-company-poised-for-growth/
0 · Reply
valueforme
valueforme Aug. 21 at 5:10 AM
$PRQR By "like these" he meant $DICE and $MORF deals, early ish stage assets, novel science.
0 · Reply
macroaxis
macroaxis Aug. 14 at 11:17 PM
$NERV - Investment perspective on Minerva Neurosciences vs. Dice Molecules ( $DICE ) in September 2023. Next fiscal quarter end is on 30th of September 2023 https://www.macroaxis.com/competition/NERV/DICE/Minerva-vs-Dice #portfolio_prospective #better_portfolio #diversify
0 · Reply
ChartMill
ChartMill Aug. 11 at 4:24 PM
$NVO, $DICE and $BLDR. Strong technicals stocks and near a new high. https://www.chartmill.com/stock/stock-screener?sid=16&f=p_pg10,v1_50b500,s_str,s_nnh,exch_us&v=3&timeframe=DAILY&type=CANDLES&months=0.05&width=720&cl=F&o1=3&o2=3&o3=1&op1=200,16711680&op2=50,255&utm_source=Strong_Stocks_near_New_High&utm_medium=stocktwits&utm_campaign=screen
0 · Reply